NephroGenex, a North Carolina-based biotech company specializing in kidney disease, has raised $3.3 million for its $26.8 million Series A funding round. Investors include Care Capital, drug developer BioStratum and
NephroGenex, a North Carolina-based biotech company specializing in kidney disease, has raised $3.3 million for its $26.8 million Series A funding round. Investors include Care Capital, drug developer BioStratum and
Copyright PEI Media
Not for publication, email or dissemination